Skip to Content

LBA 18: Improvement in Survival with the Addition of Talazoparib to First-Line Enzalutamide Treatment in RR-Deficient mCRPC Patients

The TALAPRO-2 study showed a significant improvement in overall survival in men with mCRPC treated with the combination of talazoparib and enzalutamide, regardless of whether they had HRR gene alterations. In this sub-analysis, men without HRR-deficient cancers or with unknown HRR status had a modest clinical benefit.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top